Objective: Our study was to explore the roles between serum soluble suppression of tumorigenicity 2 (sST2) and N-terminal pro-brain natriuretic peptide (NT-proBNP) while evaluating ventricular function to properly diagnose chronic heart failure (CHF). 
| INTRODUCTION
Heart failure (HF) is a pivotal public health issue which influences over 5.7 million American people and takes $37.2 billion every year and its morbidity reaches epidemic proportions. 1 Moreover, it is evaluated that 45% of women and 59% of men die in 5 years after a HF diagnosis.
2
Chronic HF (CHF) is a long-term product of heart failure, is usually managed by treating symptoms and patients suffering from deteriorating symptoms and signs may need hospitalization or more frequent doctor visits. 3 The most common causes of HF are as follow: coronary artery disease, high blood pressure, atrial fibrillation, previous myocardial infarction (heart attack), valvular heart disease, cardiomyopathy, infection,
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and excessive alcohol consumption. [4] [5] [6] The prevalence and occurrence of HF progressively increases with age, with the most affected age group being over 50 years. 3 In developed countries, 1%-2% of the adult population suffers from HF, increasing to ≥10% for those older than 70 years. 7 The National Institute for Health and Care Excellence (NICE) recommends measurement of brain natriuretic peptide combined with an ultrasound of the heart in the occurrence of symptom development.
Up until now no elite diagnostic criterion has been established for HF.
Suppression of tumorigenicity 2 (ST2), namely an interleukin (IL)-33
related receptor, is expressed by hematopoietic and epithelial cells regulating Th2-type responses. 8 ST2 is localized to the cell surface (ST2L), which can also be produced in its soluble form (soluble ST2) to function as a decoy receptor. 9, 10 It is a result of cardiomyocyte stress along with fibrosis, which can offer incremental value to natriuretic peptides for risk stratification of patients suffering from various cardiovascular diseases. 11 Brain natriuretic peptide (BNP) is mainly released from ventricular myocytes as a direct response to myocardial stretch and overloaded intracardiac pressure. 12 When released into circulation, the BNP splits into active C-terminal BNP and inactive N-terminal pro-brain natriuretic peptide (NT-proBNP) fragments. 13 Previously mentioned above, NT-proBNP concentration is elevated in the event of a cardiac impairment. NT-proBNP also exhibits longer biological half-life, measuring of which aids in the emergency diagnosis of HF. 14, 15 Interestingly enough, growing evidence supports the idea that sST2 and NT-proBNP play important roles as significant diagnostic indicators for CHF. 13, 16 However, Hughes et al. 17 demonstrated that sST2 may not be useful in predicting the incidence of cardiovascular events or HF. At the same time, NT-proBNP has been studied in CHF patients with other predictors, and no data support the role of sST2 and NT-proBNP combination in evaluating ventricular function and in turn diagnosing CHF. 18 Due to the presence of this conflicting data, we studied the diagnostic value of serum sST2 and NT-proBNP in adherence to CHF.
| MATERIALS AND METHODS

| Study subjects
One hundred and ninety-seven CHF patients were selected ran- were also included in this study serving as the normal control group during the same period. For these healthy individuals, routine laboratory blood and urine tests, liver and kidney function tests, color Doppler ultrasounds of heart, and chest X-rays were all found at normal levels.
The Ethics Committee of the First Rehabilitation Hospital of Shanghai approved this protocol. In addition, to further this study, written informed consents were obtained from each participating subject.
| New York Heart Association Functional Classification (NYHA)
In accordance with NYHA, all patients were classified into the ventricular function class II, III, and IV. 20 Patients in NYHA class I showed no symptoms and no limitations during ordinary physical activities, eg, no palpitation, no angina pectoris, or shortness of breath when walking or climbing stairs. While patients included in Class II showed mild symptoms (mild shortness of breath and/or angina) and slight limitations during ordinary activities, the patients were found to be comfortable at rest with limited exertion. Patients who belonged to Class III showed marked limitations in activities due to heightened results of their symptoms, even during less-than-ordinary activities such as walking short distances (20-100 m). The patients in Class III were only found to be comfortable while at rest; whereas the patients included in Class IV exhibited severe limitations in ordinary physical activities. Any physical activity that brought discomfort and showed symptoms occurred at rest also.
| Sample collection
All subjects were fasting and 20 mL of venous blood was extracted from each subject. Each sample was divided evenly and put into two tubes. One tube with blood coagulation accelerator added was centrifuged (2054 g) at 4°C for 15 minutes with serum obtained, whereas
another tube was added with anticoagulant agent. All samples needed to be preserved in a −80°C refrigerator without repeated thawing if they were not detected in time.
| Detection methods
To detect concentration of sST2, an enzyme-linked immunosorbent assay (ELISA) Kit (Shanghai Research Institute for Enzyme-linked Biology, Shanghai, China) was implemented. A standard curve for the sST2 concentration was plotted with the sST2 concentration as the X-axis and optical density (OD) as the Y-axis. The corresponding sST2 concentration was found according to the OD value in the standard curve, multiplying with the dilution ratio for the real concentration of the sST2 in serum samples.
The concentration of NT-proBNP was determined using the electro-chemiluminescence immunoassay analyzer (Cobas E411, F.
Hoffmann-La Roche CO, Ltd, Basel, Switzerland) and the detection kit, namely the Human N end forebrain natriuretic peptide assay kit provided by Roche Diagnostics CO, Ltd (Shanghai, China). The blood sample was added into the electro-chemiluminescence immunoassay analyzer according to the instructions of the kit with the real concentration of the NT-proBNP in samples being detected.
An automatic biochemical analyzer (Automatic biochemical analyzer 7180, Hitachi Ltd, Tokyo, Japan) was used to determine the levels of blood urea nitrogen (BUN), creatinine(Cr), alanine aminotransferase (ALT), triglyceride(TG), high-density lipoprotein cholesterol (HDL-C), low-density lipoprotein cholesterol (LDL-C), and uric acid (UA).
| Statistical analysis
Data were analyzed using the statistical package for the social sciences 
| RESULTS
| Baseline characteristics of subjects
No significant differences in gender, age, weight, heart rate, body mass index (BMI), BUN, ALT, and TG between the CHF patients belonged to different classes of ventricular function and the control subjects.
However, the levels of UA, Cr, HDL-C, and LDL-C exhibited significant differences (P<.05, Table 1 ).
| Comparisons of serum ST2 and NT-ProBNP levels among four groups
The sST2 and NT-ProBNP concentrations were higher in the ventricular function II, III, and IV than concentrations in the normal control group (P<.05). Severity-dependent manners showed in the concentrations of sST2 and NT-ProBNP (P<.05, Figure 1 ).
| Correlations of serum sST2 and NT-ProBNP levels with NYHA and clinical features among four groups
Spearman's correlation analysis was adopted to detect the correla- especially among CHF patients. They are also in positive correlation with the ventricular function classification (Tables 2 and 3 ).
| Relevance of serum sST2 and NT-ProBNP levels as diagnostic indicators of CHF
The ROC curve indicated that the area under the curve of sST2 was found/calculated to be 0.942 (95% CI: 0.917-0.966) and the AUC of NT-proBNP was found/calculated to be 0.920 (95% CI: 0.891-0.948).
The AUC of the sST2+NT-proBNP curve was found to be 0.968 (95% CI: 0.953-0.984) and the combination of sST2 and NT-proBNP had a sensitivity of 85.3% and specificity of 97.2%. These results suggested that sST2 combined with NT-ProBNP may be a better diagnostic M, male; F, female; HR, heart rate; BMI, body mass index; BUN, blood urea nitrogen; Cr, creatinine; ALT, alanine aminotransferase, UA, uric acid; TG, triglyceride; HDL-C, high-density lipoprotein cholesterol, LDL-C, lowdensity lipoprotein cholesterol; sST2, serum soluble suppression of tumorigenicity 2; NT-proBNP, amino-terminal pro-brain natriuretic peptide; CHF, chronic heart failure. M, male; F, female; HR, heart rate; BMI, body mass index; BUN, blood urea nitrogen; Cr, creatinine; ALT, alanine aminotransferase, UA, uric acid; TG, triglyceride; HDL-C, high-density lipoprotein cholesterol, LDL-C, lowdensity lipoprotein cholesterol; sST2, serum soluble suppression of tumorigenicity 2; NT-proBNP, amino-terminal pro-brain natriuretic peptide; CHF, chronic heart failure; NYHA, New York Heart Association Functional Classification.
T A B L E 3 Correlation analyses for the concentrations of sST2 and NT-ProBNP with baseline characteristics of CHF patients
indicator for CHF ( Figure 2 and Table 4 ). Association between CHF and sST2, NT-proBNP, UA, Cr, HDL-C, and LDL-C was examined with binary logistic regression analysis, demonstrating that sST2 (OR=1.148, 95% CI: 1.052-1.253), NT-proBNP (OR=1.012, 95% CI: 1.000-1.023), UA (OR=1.084, 95% CI: 1.036-1.133), and Cr (OR=1.187, 95% CI:
1.068-1.320) were the risk factors for CHF, whereas the HDL-C and LDL-C had no relation with the occurrence of CHF (P>.05).
| DISCUSSION
Chronic heart failure is a leading public health problem and its occurrence is rapidly increasing. 21 Although recent decades have witnessed great achievements in it treatment, the mortality of HF patients continues to increase. Initially, our study demonstrated that the levels of UA, Cr, and LDL-C were increased but the level of HDL-C was decreased with the severity of ventricular dysfunction. Zhang et al. 23 
also reported
that serum UA level correlated with the severity of ventricular dysfunction and could be adapted as an independent predictor of death in patients with CHF. Vizzardi et al. 24 advocated that serum
Cr levels exhibited an independent prognostic value for cardiovascular diseases. HDL-C levels were found to supply cardiovascular protection by facilitating reverse cholesterol transport from macrophages. 25 Rohatgi et al. 26 demonstrated that a low HDL-C level is one of the risk factors for the occurrence and progression of atherosclerotic cardiovascular disease. Finally, Imano et al. 27 demonstrated that a high LDL-C level was positively related with the risk of CHF.
However, by logistic regression analysis among UA, Cr, LDL-C, and HDL-C, only UA and Cr were found to be risk factors of CHF. An explanation for this could be provided by the fact that CHF resulted from a wide spectrum of cardiovascular diseases. 4 In addition, a relatively small sample size may contribute in the weak association between LDL-C and HDL-C levels and ventricular dysfunction in CHF patients. To be more precise, a performance of a large cohort study would be necessary.
Essentially, our findings suggested that the sST2 and NTProBNP concentrations increased significantly in the CHF patients than those in the healthy control subject groups, showing severitydependent manners. The sST2 concentration plays an important role in inflammation and fibrosis, both of which are promoted in CHF, leading to adverse ventricular remodeling. 28 As shown in a study reported by Weinberg et al. 29 patients with severe chronic NYHA class III to IV HF, the alternations of sST2 levels were an indicator in predicting subsequent death or transplantation. Usually requiring prolonged volume and pressure-overload induced ventricular wall expansion, the release of BNP was primarily regulated at the transcriptional level. 12 Although BNP and NT-ProBNP were equally released, the NT-ProBNP with higher molecular weight and longer half-life had higher serum levels than BNP and might have been a more sensitive indicator of cardiac function. 30 Consistent with our study, Mir et al. 31 reported that NT-ProBNP concentration was significantly increased in patients with congestive HF, possibly reflecting the degree of cardiac dysfunction. Januzzi et al. 30 found that the diagnostic threshold of NT-ProBNP was 443 mg/L which only above could be used to diagnose HF. Consequently, the concentrations of sST2 and NT-ProBNP were associated with the severity of CHF, in turn reflecting ventricular function. In addition, the diagnostic value of sST2, NT-ProBNP, and the presence of their combination in CHF was detected and it was also revealed that the combination of sST2
and NT-ProBNP was a better diagnostic indicator than sST2 and NTProBNP individually for CHF. Consistently, Bayes-Genis et al. 21 attempts to explore the combined usefulness of ST2 and NT-proBNP to promote the prediction of mortality in CHF. It is believed that our study coupled with that of Bayes-Genis et al. will highlight the combined usefulness of sST2 and NT-proBNP in clinical practice for diagnosing CHF.
Nevertheless, the two investigated indicators were analyzed in frozen samples. The risk of this method of analyzation being that the absolute levels of sST2 and NT-ProBNP could be influenced by measurement deviation from frozen instead of fresh samples. Besides, CHF is a multifactorial disease and a larger cohort study would be further required to eliminate bias. In spite of all these limitations, our study provides evidence that sST2, NT-proBNP, UA, and Cr as risk fac- YP15M02). We would like to acknowledge the helpful comments on this study received from our reviewers.
